Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation

Heart

Volumn 82, Issue 4, 1999, Pages 486-493

  Tuinenburg, A E ^a   Van Gelder, I C ^a   Van Den Berg, M P ^a   Brugemann J ^a   De Kam, P J ^a   Crijns, H J G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atrial fibrillation; Cardioversion; Heart failure

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CARDIOVERSION; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RISK FACTOR; SINUS RHYTHM; VALVULAR HEART DISEASE;

EID: 0032847045     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.82.4.486     Document Type: Article

References (38)

1. 1 Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-22.
2. 2 Onundarson PT, Thorgeirsson G, Jonmundsson E, et al. Chronic atrial fibrillation - epidemiologic features and 14 year follow-up: a case control study. Eur Heart J 1987;8:521-7.
3. 3 Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155: 469-73.
4. 4 Cameron A, Schwartz MJ, Kronmal RA, et al. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988;61:714-17.
5. 5 Krahn AD, Manfreda J, Tate RE, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84.
6. 6 Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991;84:40-8.
7. 7 Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl 6):102-10.
8. 8 Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
9. 9 Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204.
10. 10 Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-63.
11. 11 Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585-92.
12. 12 Van Gelder IC, Crijns HJGM, van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68: 41-6.
13. 13 Gosselink ATM, Crijns HJGM, Van Gelder IC, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-93.
14. 14 Crijns HJGM, Van Gelder IC, van Gilst WH, et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-41.
15. 15 Crijns HJGM, Van Gelder IC, Tieleman RG, et al. Long-term outcome of electrical cardioversion in patients with chronic atrial flutter. Heart 1997;77:56-61.
16. 16 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
17. 17 Fowler NO, van der Bel Kahn JM. Indications for surgical replacement of the mitral valve. With particular reference to common and uncommon causes of mitral regurgitation. Am J Cardiol 1979;44:148-57.
18. 18 Shapira N, Lemole GM, Fernandez J, et al. Aortic valve repair for aortic stenosis in adults. Ann Thorac Surg 1990;50:110-20.
19. 19 Hoshino PK, Gaasch WH. When to intervene in chronic aortic regurgitation. Arch Intern Med 1986;146:349-52.
20. 20 Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
21. 21 Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997;20:1603-5.
22. 22 Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840-4.
23. 23 Rodriguez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137-41.
24. 24 Heinz G, Siostrzonek P, Kreiner G, et al. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 1992;69:489-92.
25. 25 Grogan M, Smith HC, Gersh BJ, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-3.
26. 26 Crijns HJGM, Van den Berg MP, Van Gelder IC, et al. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997;18(suppl C):45-9.
27. 27 Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996;78:1433-6.
28. 28 Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997;30:1039-45.
29. 29 Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
30. 30 Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-32.
31. 31 Carlsson J, Tebbe U, Rox J, et al. Cardioversion of atrial fibrillation in the elderly. ALKK-Study Group. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausaerzte. Am J Cardiol 1996;78:1380-4.
32. 32 Van den Berg MP, Tuinenburg AE, Crijns HJGM, et al. Heart failure and atrial fibrillation: current concepts and controversies. Heart 1997;77:309-13.
33. 33 Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-4.
34. 34 Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-71.
35. 35 Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham study. JAMA 1985;254:3449-53.
36. 36 Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74.
37. 37 The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management - the AFFIRM study design. Am J Cardiol 1997;79:1198-202.
38. 38 Hohnloser SH, Kuck KH. Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial. Pacing Clin Electrophysiol 1997;20:1989-92.